Verifying what we "think" we know would be great. We think that Mayo is honest, efficient, and correct about the "miracle" properties of Imetelstat. The problem is that most of the investing world does not believe their results for one reason or another. ASH, I hope, will bring these out the "truth", and that should be very positive for investors and patients. There is always that feeling that something "bad" has been missed, but it is nowhere in sight. ASH should be a positive experience for all IMET supporters. ASH abstracts are almost here (Nov. 6).
There is nothing to hold IMET back; No significant side effects, Works, Unique. Spike in price near & connected to ASH abstracts.
A paralysed man has been able to walk again after a pioneering therapy that involved transplanting cells from his nasal cavity into his spinal cord.
Darek Fidyka, who was paralysed from the chest down in a knife attack in 2010, can now walk using a frame.
The treatment, a world first, was carried out by surgeons in Poland in collaboration with scientists in London.
“I have waited 40 years for something like this”
Prof Wagih El Masri
Consultant spinal injuries surgeon
(Details of the research are published in the journal Cell Transplantation.)
Darek Fidyka, 40, from Poland, was paralysed after being stabbed repeatedly in the back in the 2010 attack.
He said walking again - with the support of a frame - was "an incredible feeling", adding: "When you can't feel almost half your body, you are helpless, but when it starts coming back it's like you were born again."
Prof Geoff Raisman, chair of neural regeneration at University College London's Institute of Neurology, led the UK research team.
He said what had been achieved was "more impressive than man walking on the moon".
I am looking for the IMET negatives. I see no significant side-effects, and no claim from Mayo (MF studies) or anyone else that IMET does not work. The FDA has no reason to keep IMET off of the market, and out of the hands of needy patients. The conclusion has to be that the FDA is on Mayo's and IMET's side, and Mayo is calling the "shots". ASH will tell all.
The FDA has no creditable medical or scientific reasons for any hold that involves IMET and liver-functions. The FDA, as an honest broker, having used an "abundance of caution", is about to release the last vestiges of any such hold. ASH will see to that. Very positive news about IMET will start with the ASH abstracts.
I wasn't aware of these foreign trials (Germany, Switzerland) and the apparent successes (recent posts) for IMET. It is often the case that approvals are granted in Europe before the USA. Perhaps that has been the plan all along. Novartis and Roche have important blood cancer programs
There is really nothing to do now, but wait for ASH news. ASH will make or break IMET (make, I think). Geron's PPS will reflect this, but Geron has its own identity that is separate from IMET. Geron will be merged out of existence, or team-up with a powerful partner, most likely.
There is a timely convergence taking place between ASH abstracts, and the repair of the FDA-Mayo-Geron problems caused by the low level-liver-considerations (holds). The market is taking note. In addition the telomere-telomerase bond has potential well beyond the MF successes. There is potential in combination drugs (Amgen, Yale) and in pediatric tumors (NCI) and pancreatic cancers.
There is a timely convergence taking place between ASH abstracts, and the repair of the FDA-Mayo-Geron problems caused by the low level-liver-considerations (holds). The market is talking note. In addition the telomere-telomerase bond has potential well beyond the MF successes.
Everything looks positive for IMET. ASH abstracts (Nov. 6) and ASH (Dec. 6) will tell us all we need to know about the current science and medical progress. The "Geron-story" is still being written. Thanks again for the upbeat summery.
"Telomeres–the terminal caps of chromosomes–become shorter as individuals age, and there is much interest in determining what causes telomere attrition since this process may play a role in biological aging. The leading hypothesis is that telomere attrition is due to inflammation, exposure to infectious agents, and other types of oxidative stress, which damage telomeres and impair their repair mechanisms. Several lines of evidence support this hypothesis, including observational findings that people exposed to infectious diseases have shorter telomeres. Experimental tests are still needed. "
In a strange way, the interest in IMET (cancer, non-infectious) has increased with infectious disease considerations (Ebola). Geron is about to become a market leader, as ASH abstracts (Nov. 6) and ASH (Dec. 6) presentations become public information. Human survival is front and center.
"I think the Tefferi abstract will contain positive news about the IMET 23 on MF with implicit info on the IMETALSTAT 33 who we know we're only allowed to continue on IMET if they were benefiting." (from end2war).
I agree with this. I don't see how the PPS can be held down much longer.
1. "HOPING & PRAYING ASH"---That is exactly what I am doing, but I believe science, medicine and the Mayo Clinic are on my side.
2. "The best and brightest with the DEEPEST pockets"--These are the people that will be listening to all presentations at ASH, and will make their decisions accordingly.
3. "retail clowns"---They are selling, and the stock is passing into stronger, wiser hands.
The PPS will trend upward as we get closer to ASH. Dr. T's abstract around Nov. 6 will be of great interest to all parties. The ongoing relations between Geron, Mayo, the FDA, and perhaps other drug companies will be sorted out (at least in part) before ASH (Dec. 6). Geron is the "market-maker" and Mayo is the "medicine-man". Imetelstat (IMET) is the medicine and Geron is the current owner. I see nothing that is negative about IMET, so the positive news will be the major market-event that will determine the PPS.
The PPS will trend upward as we get closer to ASH. Dr. T's abstract around Nov. 6 will be of great interest. The ongoing relations between Geron, Mayo, the FDA, and perhaps other drug companies will be sorted out (at least in part) before ASH (Dec. 6). Geron is the "market-maker" and Mayo is the "medicine-man". Imetelstat (IMET) is the medicine and Geron is the current owner.
I like beaver's response. To take it a bit further, you are a very ignorant and uninformed individual. For you to be correct, all of Mayo Clinic would have to be fraudulent and corrupt. The chances of that are ZERO. Imetelstat will be categorized as a good, great or miracle drug. Geron will be merged out of existence, or will partner with a deep-pocketed drug company. The PPS is going up; the question is how high. As far as your "never $2 again guarantee", that is impossible.